We propose a Pediatric Pharmacology Research Unit (PPRU) at University of Texas Southwestern Medical Center (UTSWMC) and Children's Medical Center of Dallas (CMC) in response to the RFA-HD-03-D01. We have more than 35 years of experience in designing and conducting clinical trials in newborns, infants and older children. CMC is a 350 bed, major pediatric primary and tertiary care facility in North Texas with a diverse patient population, and with one of the busiest pediatric emergency rooms and intensive care units in the country. Its newborn nursery located within the adjacent Parkland Memorial Hospital is one of the largest in the county, with over 16,000 live births annually. It is equiped with in-patient and out-patient monitoring units. The CMC pharmacy has participated in more than 500 research studies and has full time research pharmacists. We have access to an analytical laboratory that specializes in developing and validating new assays for drug monitoring. We have one of the oldest and largest pediatric infectious disease fellowship training programs in the US and also participate in training PharmD residents. Because of these extensive resources and experienced support services, a PPRU at Dallas will help advance the overall pediatric pharmacologic research including pharmacokinetics, pharmacodynamics, safety and efficacy studies. The specific of the unit are the following: 1- To be a PPRU center to conduct pharmcokinetics, drug-bioalvailability, formulation, safety, tolerability and efficiacy trials in pediatrics 2- To gather data for age-specific labeling of drugs in pediatrics 3- To conduct research in novel areas of pediatric pharmacology 4- To apply pharmacogenoflhics to better understand and treat diseases of infants and children 5- To develop and apply proteomics for pathogenesis and pediatric pharmacology studies 6- To develop the PPRU as a resource for teaching and training pharmacy students, PharmD residents and fellows, pediatric sub-specialty fellows., and the Associate Pediatric Pharmacologist We will actively collaborate with the network by providing protocols that could be conducted by centers in the network and by participating in trials brought forward by other units.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZHD1-DSR-A (01))
Program Officer
Giacoia, George
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Sw Medical Center Dallas
Schools of Medicine
United States
Zip Code
Schimpf, Karen J; Meek, Claudia C; Leff, Richard D et al. (2015) Quantification of myo-inositol, 1,5-anhydro- D-sorbitol, and D-chiro-inositol using high-performance liquid chromatography with electrochemical detection in very small volume clinical samples. Biomed Chromatogr 29:1629-36
Phelps, Dale L; Ward, Robert M; Williams, Rick L et al. (2013) Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk. Pediatr Res 74:721-9
Greer, Laura G; Leff, Richard D; Rogers, Vanessa Laibl et al. (2011) Pharmacokinetics of oseltamivir according to trimester of pregnancy. Am J Obstet Gynecol 204:S89-93
Greer, Laura G; Leff, Richard D; Rogers, Vanessa Laibl et al. (2011) Pharmacokinetics of oseltamivir in breast milk and maternal plasma. Am J Obstet Gynecol 204:524.e1-4
Blumer, Jeffrey; Rodriguez, Adib; Sánchez, Pablo J et al. (2010) Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children. Antimicrob Agents Chemother 54:2032-41
Benjamin Jr, D K; Smith, P B; Arrieta, A et al. (2010) Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 87:93-9
Abdel-Rahman, Susan M; Benziger, David P; Jacobs, Richard F et al. (2008) Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 27:330-4
Santos, Roberto P; Sanchez, Pablo J; Mejias, Asuncion et al. (2007) Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatr Infect Dis J 26:364-6
Mejias, Asuncion; Chavez-Bueno, Susana; Raynor, Martin B et al. (2007) Motavizumab, a neutralizing anti-Respiratory Syncytial Virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model. Virol J 4:109